SCHEMBL708797

SCHEMBL708797

CC(C)(C)OC(=O)N1CC2C(CNCc3ccc(F)c(Cl)c3)C2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.42
CNR2 P34972 1/20 0.41
NPSR1 Q6W5P4 2/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
P2RX7 Q99572 1/20 0.39
ANO1 Q5XXA6 1/20 0.39
NAMPT P43490 1/20 0.39
JAK3 P52333 1/20 0.38
SLC6A9 P48067 1/20 0.38
KCNH2 Q12809 1/20 0.38
KAT5 Q92993 1/20 0.38
KAT8 Q9H7Z6 1/20 0.38
CCNT1 O60563 1/20 0.38
PDGFRB P09619 1/20 0.38
KDR P35968 1/20 0.38
TACR1 P25103 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
STS P08842 1/20 0.38
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116386 0.87 SMN1; SMN2 (0.50) USP30NPSR1HTTSMN1; SMN2ANO1
SCHEMBL712554 0.87 P2RX7 (0.46) USP30P2RX7NAMPTJAK3PDGFRB
SCHEMBL712166 0.85 SMN1; SMN2 (0.47) SMN1; SMN2P2RX7ANO1NAMPTJAK3
SCHEMBL710560 0.80 TACR1 (0.50) P2RX7NAMPTTACR1
SCHEMBL3765926 0.79 SLC6A9 (0.47) CNR2SLC6A9KCNH2MAPT
SCHEMBL710769 0.78 GLS (0.44) NAMPTSLC6A9KCNH2TACR1GPR119
SCHEMBL3770883 0.77 PRMT5 (0.38) CNR2P2RX7SLC6A9KCNH2
SCHEMBL4319076 0.75 EPHX2 (0.50) CCNT1STS
SCHEMBL20765938 0.74 NAMPT (0.53) SMN1; SMN2NAMPTKCNH2TACR1GPR119
SCHEMBL3771852 0.74 SLC6A9 (0.42) CNR2SLC6A9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-8124639-B2 Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. (US) 2012-02-28 US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 USP30 4308/4885CNR2 439/4885NPSR1 382/4885
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors SLC1A2, SLC1A1, GLRA1 USP30 4163/4885CNR2 430/4885NPSR1 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.